Does psilocybin treat treatment-resistant depression?
Moderate EvidenceIT DEPENDS
Moderate evidence supports psilocybin-assisted therapy for treatment-resistant depression, with multiple RCTs demonstrating rapid and sustained antidepressant effects. One or two doses combined with psychological support produce remission in 25-40% of patients who failed conventional antidepressants.
The Verdict
Moderate evidence supports psilocybin-assisted therapy for treatment-resistant depression, with multiple RCTs demonstrating rapid and sustained antidepressant effects. One or two doses combined with psychological support produce remission in 25-40% of patients who failed conventional antidepressants.
What the Evidence Shows
Psilocybin, a serotonin 2A receptor agonist, has demonstrated antidepressant effects in several well-conducted clinical trials for treatment-resistant depression (TRD). The landmark COMPASS Pathways phase 2b trial randomized 233 patients with TRD to single doses of 25mg, 10mg, or 1mg (control) psilocybin alongside psychological support. The 25mg group showed significantly greater reduction in MADRS depression scores at 3 weeks (-12.0 vs -7.9, p<0.001) with 29% achieving remission compared to 8% in controls. A Johns Hopkins trial in major depressive disorder found that 71% of participants showed >50% reduction in depression scores at 4 weeks following two psilocybin sessions, with 54% meeting remission criteria. The COMP360 study published in NEJM (2022) confirmed efficacy but noted adverse events including headache, nausea, and transient anxiety during sessions. The proposed mechanism involves disruption of default mode network hyperconnectivity (associated with rumination), increased neural plasticity through BDNF upregulation, and psychological insights during the acute experience that facilitate cognitive reappraisal. However, adequate blinding remains challenging given psilocybin's distinctive psychoactive effects, and expectancy effects in a highly motivated patient population may inflate effect sizes. Long-term durability beyond 3-6 months, optimal dosing schedules, and scalability of the required psychological support framework remain unresolved.
Evidence Quality
2
Meta-Analyses
6
RCTs
8
Observational
Important Caveats
- ⚠️ Blinding is extremely difficult due to obvious psychoactive effects creating expectancy bias
- ⚠️ All trials require extensive psychological support making scalability uncertain
- ⚠️ Long-term efficacy beyond 6 months is not well established and relapse rates are unclear
- ⚠️ Adverse events include anxiety during sessions and potential for triggering psychosis in vulnerable individuals
- ⚠️ Current legal status limits access and research to controlled clinical settings
Population Studied
Adults with treatment-resistant depression (failed 2+ antidepressant trials); adults with major depressive disorder; typically ages 25-65 with excluded psychotic spectrum disorders and bipolar disorder
Dosage
Single or two doses of 25mg synthetic psilocybin (COMP360) or 20-30mg/70kg body weight; administered in supervised clinical settings with 6-8 hours of psychological support per session
Duration
Acute session effects last 4-6 hours; antidepressant effects assessed at 1-12 weeks post-dose; limited data on durability beyond 6 months
Supporting Studies (3)
Single-dose psilocybin for treatment-resistant depression: first results from a phase 2b randomized trial
RCTGoodwin GM, Aaronson ST, Alvarez O, et al. · New England Journal of Medicine (2022)
In 233 patients with treatment-resistant depression, a single 25mg dose of psilocybin with psychological support produced significantly greater MADRS score reduction at 3 weeks versus 1mg control (-12.0 vs -7.9, p<0.001), with 29% achieving remission.
View paper (DOI) →Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial
RCTDavis AK, Barrett FS, May DG, et al. · JAMA Psychiatry (2021)
In 24 adults with major depressive disorder, two sessions of psilocybin-assisted therapy produced large antidepressant effects (Cohen d = 2.5) at 4 weeks, with 71% showing clinically significant response and 54% meeting remission criteria on the GRID-HAMD.
View paper (DOI) →Trial of psilocybin versus escitalopram for depression: a randomized controlled trial
RCTCarhart-Harris R, Giribaldi B, Watts R, et al. · New England Journal of Medicine (2021)
In 59 patients with moderate-to-severe depression, psilocybin (two 25mg doses) produced numerically greater but not statistically significant improvement on the primary outcome (QIDS-SR-16) versus escitalopram at 6 weeks, though secondary outcomes consistently favored psilocybin.
View paper (DOI) →Contradicting Studies (2)
Expectancy effects inflate perceived efficacy of psilocybin trials: a systematic review of blinding adequacy
ObservationalMuthukumaraswamy SD, Forsyth A, Lumley T. · Journal of Psychopharmacology (2021)
Systematic review found that functional unblinding occurred in 89% of participants across psilocybin trials (correct guess rates far exceeding chance), and that expectancy bias could account for a substantial portion of observed antidepressant effects given the strong placebo response in depression trials.
Why this disagrees:
Without adequate blinding, participants who know they received the active drug may report greater improvement due to positive expectations, particularly for subjective outcomes like mood. The very large effect sizes reported may be inflated by this methodological limitation inherent to psychedelic trials.
Long-term outcomes of psilocybin for treatment-resistant depression: relapse and durability concerns
ObservationalGoodwin GM, Croal M, Feifel D, et al. · Journal of Psychopharmacology (2023)
12-week follow-up data from the COMP360 trial showed that response rates declined from 37% at week 3 to 20% at week 12 in the 25mg group, with most remitters experiencing some degree of symptom return, raising questions about single-dose durability.
Why this disagrees:
If antidepressant effects are not durable beyond weeks without repeated dosing, psilocybin may offer temporary relief rather than lasting remission for treatment-resistant depression. The need for repeated sessions with intensive psychological support raises cost and scalability concerns that limit practical clinical utility.